SCHEMBL3436249

SCHEMBL3436249

CCOC(=O)c1ccc(N2CCN(C(=O)OCC)CC2)c(N)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT1 Q99873 1/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ MAPT P10636 9/20 0.58
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ NPC1 O15118 4/20 0.55
▸ KDM4E B2RXH2 4/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ ALDH1A1 P00352 5/20 0.55
▸ HPGD P15428 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ ALOX15 P16050 2/20 0.55
▸ LMNA P02545 2/20 0.55
▸ TSHR P16473 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ GAA P10253 2/20 0.53
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14804765 0.88 KDM4E (0.71) PRMT1L3MBTL1MAPTNPC1KDM4E
SCHEMBL10049116 0.87 KDM4E (0.73) PRMT1L3MBTL1MAPTNPC1KDM4E
SCHEMBL24478835 0.81 PRMT1 (1.00) PRMT1MEN1KMT2ANPC1KDM4E
SCHEMBL3436203 0.81 MAPT (0.73) L3MBTL1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL15651250 0.80 GAA (0.72) L3MBTL1MAPTMEN1KMT2ANPC1
SCHEMBL27894380 0.79 PRMT1 (0.64) PRMT1MAPTNPC1KDM4ENPSR1
SCHEMBL20516376 0.78 P2RY12 (0.60) PRMT1L3MBTL1MAPTMEN1KMT2A
SCHEMBL8703730 0.78 MAPT (0.73) L3MBTL1MAPTMEN1KMT2AKDM4E
Ethoxycarbonyl Group SCHEMBL27894381 0.78 PRMT1 (0.57) PRMT1L3MBTL1MAPTNPC1KDM4E
SCHEMBL103154 0.78 KDM4E (0.67) PRMT1L3MBTL1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 — — EP disclosed
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 — — EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 — — US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 — — US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 — — US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 — — EP disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 — — EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 — — US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 — — US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 — — US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI PRMT1 2151/4885L3MBTL1 2920/4885MAPT 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback